Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5153228 | 1.00 | HPGD (0.33) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL5153214 | 1.00 | HPGD (0.33) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL7614513 | 0.79 | HPGD (0.33) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL7614508 | 0.79 | HPGD (0.33) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL7614503 | 0.79 | HPGD (0.33) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL5153741 | 0.77 | HPGD (0.37) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL5154377 | 0.77 | HPGD (0.37) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL5154360 | 0.77 | HPGD (0.37) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL5154355 | 0.77 | HPGD (0.37) | HPGDL3MBTL1USP2TSHRCASP1 | |
| SCHEMBL5153942 | 0.77 | HPGD (0.37) | HPGDL3MBTL1USP2TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6247906-A | — | — | None | — | — | JP | disclosed |
| EP-1367047-B1 | PROCESS FOR PRODUCING 2-HALOGENOCYCLOALKANONE OXIME | UBE INDUSTRIES (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-6881863-B2 | Process for producing 2-halogenocycloalkanone oxime | UBE INDUSTRIES, LTD. (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20040073064-A1 | Process for producing 2-halogenocycloalkanone oxime | UBE INDUSTRIES,LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1367047-A1 | PROCESS FOR PRODUCING 2-HALOGENOCYCLOALKANONE OXIME | Ube Industries, Ltd. (JP) | 2003-12-03 | — | — | EP | disclosed |
| JP-H06247906-A | PRODUCTION OF CYCLODODECYLAMINE | UBE IND LTD | 1994-09-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073064-A1 | Process for producing 2-halogenocycloalkanone oxime | PPOX, HMOX2, PDXK | HPGD 372/4885L3MBTL1 4378/4885USP2 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.